Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Ključne besede: rak analnega kanala, rak analnega roba, radiokemoterapija, obsevanje
Objavljeno v DiRROS: 15.12.2022; Ogledov: 497; Prenosov: 110
Celotno besedilo (134,47 KB)

Povzetek: Detection of germline and somatic pathogenic/likely pathogenic variants (PV/LPV) in BRCA genes is at the moment a prerequisite for use of PARP inhibitors in different treatment settings of different tumors. The aim of our study was to determine the most appropriate testing workflow in epithelial ovarian cancer (EOC) patients using germline and tumor genotyping of BRCA and other hereditary breast and/or ovarian cancer (HBOC) susceptibility genes. Consecutive patients with advanced non-mucinous EOC, who responded to platinum-based chemotherapy, were included in the study. DNA extracted from blood and FFPE tumor tissue were genotyped using NGS panels TruSightCancer/Hereditary and TruSight Tumor 170. Among 170 EOC patients, 21.8% had BRCA germline or somatic PV/LPV, and additionally 6.4% had PV/LPV in other HBOC genes. Sensitivity of tumor genotyping for detection of germline PV/LPV was 96.2% for BRCA genes and 93.3% for HBOC genes. With germline genotyping-only strategy, 58.8% of HBOC PV/LPV and 68.4% of BRCA PV/LPV were detected. By tumor genotyping-only strategy, 96.1% of HBOC PV/LPV and 97.4% of BRCA PV/LPV were detected. Genotyping of tumor first, followed by germline genotyping seems to be a reasonable approach for detection of PV/LPV in breast and/or ovarian cancer susceptibility genes in non-mucinous EOC patients.
Ključne besede: BRCA, ovarian cancer, tumor genotyping, HBOC
Objavljeno v DiRROS: 06.09.2022; Ogledov: 507; Prenosov: 275
Celotno besedilo (2,35 MB)
Gradivo ima več datotek! Več...

Povzetek: Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Ključne besede: onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer
Objavljeno v DiRROS: 24.06.2022; Ogledov: 789; Prenosov: 326
Celotno besedilo (2,03 MB)

Ključne besede: rak analnega kanala, rak analnega roba, bolniki, zdravljenje
Objavljeno v DiRROS: 18.03.2022; Ogledov: 676; Prenosov: 368
Celotno besedilo (407,06 KB)
Gradivo ima več datotek! Več...

Ključne besede: rak (medicina), epidemiologija, preventiva, dedna predispozicija, diagnostika, kirurško zdravljenje, adjuvantna terapija, sistemsko zdravljenje, radioterapija, sledenje pacientov, medicinska rehabilitacija, paliativna oskrba, elektronske knjige
Objavljeno v DiRROS: 17.03.2022; Ogledov: 681; Prenosov: 343
Celotno besedilo (883,32 KB)
Gradivo ima več datotek! Več...